Skip to content

Treatment of Fatty Liver Disease with Unani Medicine

An Open Label, Randomized, Controlled Clinical Study to Evaluate the Therapeutic Efficacy of a Specific Unani Formulation in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065391
Enrollment
60
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K77- Liver disorders in diseases classified elsewhere

Interventions

Intervention1: Unani Formulation: The Unani formulation containing extracts of Revand Chini, Afsanteen, Qust and Luk. 2 capsules of the Unani formulations will be given orally in empty stomach twice d

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of grade 1 and grade 2 Fatty Liver (up-to 290 db/m in QUS/ Fibroscan) 2. Patients willing to participate and ready to sign the written informed consent. 3. Patients diagnosed as having fatty liver based on the ultrasonography report. 4. Patients with/ without clinical signs and symptoms.

Exclusion criteria

Exclusion criteria: 1. Patients having documented fatty liver grade 3 or above. 2. Use of alcohol or any other drug abuse. 3. Patients diagnosed with any coexisting liver disease. 4. Pregnant and lactating women. 5. Patients suffering with Hypertension, CKD, CAD, CLD or uncontrolled DM, Hypothyroidism. 6. Patient having immune-compromised status. 7. Patient using lipid lowering drugs or dietary supplements within the last 3 weeks. 8. Oral contraceptives & corticosteroids. 9. Neurological disorders like epilepsy or psychiatric disorders. 10. Patient having history of Pancreatitis. 11. Acute hepatitis with raised serum bilirubin.

Design outcomes

Primary

MeasureTime frame
Improvement in Fatty liver grade assessed by QUS.Timepoint: 1st day and 90th day

Secondary

MeasureTime frame
Improvement in Liver Function Test, Improvement in Lipid profileTimepoint: 1st day and 90th day

Countries

India

Contacts

Public ContactDr Gulnaz Azmi

Jamia Hamdard

gulnaz.azmi01@gmail.com9451066452

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026